SK287143B6 - Farmaceutické kompozície obsahujúce zlúčeniny inhibujúce HIV proteázu - Google Patents

Farmaceutické kompozície obsahujúce zlúčeniny inhibujúce HIV proteázu Download PDF

Info

Publication number
SK287143B6
SK287143B6 SK1110-2002A SK11102002A SK287143B6 SK 287143 B6 SK287143 B6 SK 287143B6 SK 11102002 A SK11102002 A SK 11102002A SK 287143 B6 SK287143 B6 SK 287143B6
Authority
SK
Slovakia
Prior art keywords
amino
hydroxy
solution
amount
total weight
Prior art date
Application number
SK1110-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK11102002A3 (sk
Inventor
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287143(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of SK11102002A3 publication Critical patent/SK11102002A3/sk
Publication of SK287143B6 publication Critical patent/SK287143B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SK1110-2002A 2000-01-19 2000-12-01 Farmaceutické kompozície obsahujúce zlúčeniny inhibujúce HIV proteázu SK287143B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19
PCT/US2000/032771 WO2001052821A1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations

Publications (2)

Publication Number Publication Date
SK11102002A3 SK11102002A3 (sk) 2002-12-03
SK287143B6 true SK287143B6 (sk) 2010-01-07

Family

ID=23936923

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1110-2002A SK287143B6 (sk) 2000-01-19 2000-12-01 Farmaceutické kompozície obsahujúce zlúčeniny inhibujúce HIV proteázu

Country Status (26)

Country Link
EP (3) EP2269591B1 (bg)
JP (1) JP4769400B2 (bg)
KR (1) KR100861885B1 (bg)
CN (1) CN100536833C (bg)
AT (1) ATE395049T1 (bg)
AU (2) AU1940501A (bg)
BG (1) BG66112B1 (bg)
BR (1) BR0011864A (bg)
CA (1) CA2395987C (bg)
CY (3) CY1108197T1 (bg)
CZ (1) CZ304118B6 (bg)
DE (1) DE60038899D1 (bg)
DK (3) DK2269591T3 (bg)
ES (3) ES2304990T3 (bg)
HK (1) HK1120213A1 (bg)
HU (1) HU229778B1 (bg)
IL (2) IL150265A0 (bg)
MX (1) MXPA02007097A (bg)
NO (1) NO331400B1 (bg)
NZ (1) NZ519724A (bg)
PT (3) PT2269591T (bg)
SI (3) SI1917958T1 (bg)
SK (1) SK287143B6 (bg)
TR (1) TR201809435T4 (bg)
WO (1) WO2001052821A1 (bg)
ZA (1) ZA200205109B (bg)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (en) * 2007-08-07 2009-02-12 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
EP2714683A4 (en) 2011-05-27 2014-11-05 Hetero Research Foundation RITONAVIR AMORPH CO-PRECIPITATION
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
WO1992008701A1 (en) 1990-11-19 1992-05-29 Monsanto Company Retroviral protease inhibitors
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
BR9206623A (pt) 1991-10-11 1995-05-02 Du Pont Merck Pharma Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
EP0541168B1 (en) 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DE69300043T2 (de) 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
EP0641333B1 (en) 1992-05-20 1996-08-14 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
AU7518694A (en) 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
CA2238977A1 (en) * 1995-12-13 1997-06-19 Abbott Laboratories Retroviral protease inhibiting compounds
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MXPA01012478A (es) * 1999-06-04 2003-10-14 Abbott Lab Formulaciones farmaceuticas mejoradas.

Also Published As

Publication number Publication date
DK1917958T3 (da) 2012-09-24
WO2001052821A1 (en) 2001-07-26
CA2395987A1 (en) 2001-07-26
BR0011864A (pt) 2004-07-20
HK1120213A1 (en) 2009-03-27
EP2269591B1 (en) 2018-04-04
SI1248600T1 (sl) 2008-08-31
EP1248600B1 (en) 2008-05-14
EP1917958B1 (en) 2012-06-13
CY1112995T1 (el) 2016-04-13
SI2269591T1 (en) 2018-08-31
PL361396A1 (en) 2004-10-04
MXPA02007097A (es) 2003-01-28
NO20023455L (no) 2002-09-18
IL150265A (en) 2015-02-26
AU2006235895B2 (en) 2009-08-13
SI1917958T1 (sl) 2012-10-30
DK1248600T3 (da) 2008-09-08
ES2676151T3 (es) 2018-07-17
HU229778B1 (hu) 2014-07-28
HUP0302070A3 (en) 2007-02-28
DE60038899D1 (de) 2008-06-26
CY1108197T1 (el) 2014-02-12
PT2269591T (pt) 2018-07-09
DK2269591T3 (en) 2018-07-16
EP1917958A3 (en) 2008-08-27
NO20023455D0 (no) 2002-07-18
CA2395987C (en) 2009-12-22
CY1120408T1 (el) 2019-07-10
ATE395049T1 (de) 2008-05-15
NO331400B1 (no) 2011-12-19
IL150265A0 (en) 2002-12-01
ES2304990T3 (es) 2008-11-01
CN1424907A (zh) 2003-06-18
BG66112B1 (bg) 2011-05-31
EP1248600A1 (en) 2002-10-16
CZ304118B6 (cs) 2013-11-06
HUP0302070A2 (hu) 2003-09-29
EP1917958A2 (en) 2008-05-07
TR201809435T4 (tr) 2018-07-23
CZ20022663A3 (cs) 2002-11-13
EP2269591A2 (en) 2011-01-05
CN100536833C (zh) 2009-09-09
SK11102002A3 (sk) 2002-12-03
PT1917958E (pt) 2012-08-16
AU2006235895A1 (en) 2006-11-30
ZA200205109B (en) 2003-10-31
NZ519724A (en) 2004-07-30
JP4769400B2 (ja) 2011-09-07
JP2003533435A (ja) 2003-11-11
PT1248600E (pt) 2008-08-25
BG106976A (bg) 2003-05-30
EP2269591A3 (en) 2011-07-27
ES2387579T3 (es) 2012-09-26
KR100861885B1 (ko) 2008-10-09
KR20020082210A (ko) 2002-10-30
AU1940501A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
US7432294B2 (en) Pharmaceutical formulations
EP1183026B1 (en) Improved pharmaceutical formulations comprising ritonavir
AU2006235895B2 (en) Improved pharmaceutical formulations

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: ABBVIE INC., NORTH CHICAGO, IL, US

Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, IL, US

Effective date: 20120801

MA4A Renunciation of the patent

Effective date: 20200414